Text Size
271 studies found for:    "Multiple Sclerosis, Relapsing-Remitting"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed BG00012 Phase 2 Combination Study in Subjects With Multiple Sclerosis
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Relapsing-remitting;   Multiple Sclerosis
Intervention: Drug: BG00012
2 Terminated
Has Results 		Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Minocycline;   Drug: Placebo
3 Completed An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention:
4 Recruiting Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: GSK239512;   Drug: Placebo
5 Completed
Has Results 		A Study to Evaluate Rebif® New Formulation (IFN-beta-1a) in Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Rebif® New Formulation (IFN-beta-1a)
6 Active, not recruiting
Has Results 		A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: interferon beta-1a (Rebif®);   Biological: alemtuzumab
7 Recruiting Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: MEDI-551;   Drug: Placebo
8 Completed Safety and Efficacy Study of Daclizumab High Yield Process to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-remitting
Interventions: Biological: Daclizumab High Yield Process;   Other: placebo
9 Recruiting Melatonin in Relapsing-Remitting Multiple Sclerosis Patients
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Melatonin
10 Recruiting An Efficacy and Safety Study of BG00012 in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: BG00012
11 Completed CLARITY - Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Cladribine Tablets;   Other: Placebo
12 Recruiting Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention:
13 Withdrawn QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)
14 Completed A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-Remitting Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Rebif® 44 mcg three times per week subcutaneously (SubQ);   Drug: Avonex® 30 mcg once weekly intramuscularly (IM)
15 Completed
Has Results 		Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon beta 1b (Betaseron, BAY86-5046)
16 Recruiting A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Part A: 100 mg/mL GSK2618960;   Drug: Part A: matching placebo;   Drug: Part B: Dose of GSK2618960 decided from Part A;   Drug: Part B: matching placebo;   Drug: Part C: Dose of GSK2618960 decided from Part A and B
17 Active, not recruiting Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Rebif (Interferon beta-1a)
18 Completed Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
19 Not yet recruiting Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: RNS60 125 ml;   Drug: RNS60 250 ml;   Drug: Interferon beta 1a
20 Recruiting A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: abatacept;   Drug: Placebo
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years